Direct Oral Anticoagulation Versus Warfarin in Left Ventricular Thrombus: Pooled Analysis of Randomized Controlled Trials

• Published in: Journal of clinical pharmacology 2023-10, Vol.63 (10), p.1101-1107
• Main Authors: Sahlén, Anders Olof, Jiang, Haowen, Lau, Yee How, Cuenza, Lucky, Cader, F Aaysha, Al-Omary, Mohammed, Surunchupakorn, Purich, Ho, Ka Hei, Sung, Jonathan, Lee, Derek, Honda, Satoshi, Tan Wei Chieh, Jack, Yap, Jonathan
• Format: Article
• Language: English
• Subjects: Adverse events; Antagonists; Anticoagulants; Bayesian analysis; Bleeding; Blood clots; Clinical trials; Embolism; Embolization; Heart; Mathematical models; Medicin och hälsovetenskap; Thromboembolism; Thrombosis; Ventricle; Vitamin K; Warfarin
• ISSN: 0091-2700; 1552-4604; 1552-4604
• DOI: 10.1002/jcph.2267

Patients with impaired left ventricular (LV) function can develop LV thrombus, a potentially life-threatening condition due to risk of stroke and embolization. Conventional treatment with vitamin K antagonists (VKAs; e.g., warfarin) puts patients at risk of bleeding, and the use of direct oral anticoagulants (DOACs) appears promising, although data are scant. We searched the published English language literature for randomized controlled trials (RCTs) comparing DOACs with VKAs in LV thrombus. End points were failure to resolve, thromboembolic events (stroke, embolism), bleeding, or any adverse event (composite of thromboembolism or bleeding), or all-cause death. Data were pooled and analyzed in hierarchical Bayesian models. In three eligible RCTs, 141 patients were studied during an average of 4.6 months (53.8 patient-years; n = 71 assigned to DOAC, n = 70 assigned to VKA). A similar number of patients in each treatment arm demonstrated failure to resolve (DOAC: 14/71 vs. VKA: 15/70) and death events (3/71 vs. 4/70). However, patients on DOACs suffered fewer strokes/thromboembolic events (1/71 vs. 7/70; log odds ratio [OR], -2.02 [95% credible interval (CI ), -4.53 to -0.31]) and fewer bleeding events (2/71 vs. 9/70; log OR, -1.62 [CI , -3.43 to -0.26]), leading to fewer patients on DOACs with any adverse event versus VKAs (3/71 vs. 16/70; log OR, -1.93 [CI , -3.33 to -0.75]). In conclusion, pooled analysis of RCT data favors DOACs over VKAs in patients with LV thrombus in terms of both efficacy and safety.